Capricor Therapeutics (CAPR) Reports Q3 2025 Earnings: Better than Expected EPS, No Revenue Recognized

Biotech company Capricor Therapeutics, Inc. reported its Q3 2025 earnings on November 10, 2025: an EPS of –$0.54, beating the street consensus of –$0.54 (no upside), while revenue came in at $0.00, missing expectations by ~$480 K. During the conference call, CFO Anthony Bergmann and CEO Linda Marbán emphasized their focus on advancing clinical programs and reiterated forward‑looking statements regarding R&D timelines, regulatory progress, and cash‑burn control. They flagged possible risks around trial enrollment, regulatory inspections, and future milestone revenue streams. While revenue remained at zero in the quarter, the beat on EPS reflects the company’s tight cost management amid a biotech development phase. Investors will be watching for updates on upcoming clinical data disclosures and strategic partnerships that may trigger future inflection points. #CapricorTherapeutics #BiotechEarnings #CAPR #ClinicalDevelopment #SlimScan #GrowthStocks #CANSLIM